Pieris Pharmaceuticals, Inc.
NASDAQ: PIRS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stephen S. Yoder
- Employees
- 46
- Headquarters
- Boston, United States
- IPO year
- 2015
- Market cap
- $18.0M
- Website
- https://www.pieris.com
Loading PIRS…
Loading profile data…Frequently asked questions about PIRS
What does Pieris Pharmaceuticals, Inc. (PIRS) do?
Pieris Pharmaceuticals, Inc. is a biopharmaceutical firm in the clinical development stage, dedicated to discovering and advancing drugs based on its proprietary Anticalin technology. These Anticalin proteins are therapeutic, low-molecular-weight molecules derived from naturally occurring human lipocalins, which are found in blood plasma and oth...
Where does PIRS trade?
Pieris Pharmaceuticals, Inc. (PIRS) trades on the NASDAQ Capital Market.
What sector is PIRS in?
Pieris Pharmaceuticals, Inc. (PIRS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Pieris Pharmaceuticals, Inc.?
Stephen S. Yoder is the chief executive officer of Pieris Pharmaceuticals, Inc. (PIRS).
Where is Pieris Pharmaceuticals, Inc. headquartered?
Pieris Pharmaceuticals, Inc. is headquartered in United States.
Does PIRS pay a dividend?
Pieris Pharmaceuticals, Inc. (PIRS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PIRS go public?
Pieris Pharmaceuticals, Inc. (PIRS) completed its initial public offering in 2015.